Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

MLA

Miller, Kathy D., et al. “Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 36, no. 25, Sept. 2018, pp. 2621–29. EBSCOhost, https://doi.org/10.1200/JCO.2018.79.2028.

APA

Miller, K. D., O’Neill, A., Gradishar, W., Hobday, T. J., Goldstein, L. J., Mayer, I. A., Bloom, S., Brufsky, A. M., Tevaarwerk, A. J., Sparano, J. A., Le-Lindqwister, N. A., Hendricks, C. B., Northfelt, D. W., Dang, C. T., & Sledge, G. W., Jr. (2018). Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 36(25), 2621–2629. https://doi.org/10.1200/JCO.2018.79.2028

Chicago

Miller, Kathy D, Anne O’Neill, William Gradishar, Timothy J Hobday, Lori J Goldstein, Ingrid A Mayer, Stuart Bloom, et al. 2018. “Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36 (25): 2621–29. doi:10.1200/JCO.2018.79.2028.